DexCom (NASDAQ:DXCM) Director Nicholas Augustinos Sells 6,539 Shares of Stock

Key Points

• DexCom director Nicholas Augustinos sold 6,539 shares for approximately $549,538 under a pre-arranged Rule 10b5-1 trading plan, reducing his direct ownership by 18.25%. He also sold 1,550 shares the prior day.
• DexCom shares rose 1.0% to $87.34, while the company reported quarterly earnings of $0.70 per share—beating estimates—and revenue of $1.31 billion, up 13.1% year over year.
• Analysts maintain a broadly positive view, with the stock carrying a consensus “Moderate Buy” rating and an average price target of $88.71; institutional investors own 97.75% of outstanding shares.

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) Director Nicholas Augustinos sold 6,539 shares of the firm's stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total transaction of $549,537.56. Following the transaction, the director directly owned 29,293 shares of the company's stock, valued at approximately $2,461,783.72. This represents a 18.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nicholas Augustinos also recently made the following trade(s):

• On Monday, September 14th, Nicholas Augustinos sold 1,550 shares of DexCom stock. The shares were sold at an average price of $84.02, for a total transaction of $130,231.00.

DexCom Stock Up 1.0%

Shares of DXCM stock traded up $0.89 during trading hours on Wednesday, hitting $87.34. 3,541,974 shares of the company were exchanged, compared to its average volume of 5,115,788. The stock has a market capitalization of $32.96 billion, a price-to-earnings ratio of 34.52, a P/E/G ratio of 1.42 and a beta of 1.42. DexCom, Inc. has a one year low of $54.11 and a one year high of $92.59. The business's 50-day simple moving average is $83.25 and its two-hundred day simple moving average is $72.98. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. During the same period in the previous year, the company earned $0.48 earnings per share. DexCom's quarterly revenue was up 13.1% on a year-over-year basis. Sell-side analysts predict that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Institutional Trading of DexCom

Hedge funds have recently bought and sold shares of the company. Sequoia Financial Advisors LLC lifted its stake in DexCom by 15.1% during the second quarter. Sequoia Financial Advisors LLC now owns 19,116 shares of the medical device company's stock valued at $1,287,000 after buying an additional 2,509 shares in the last quarter. Tidal Investments LLC lifted its position in shares of DexCom by 6.5% in the 2nd quarter. Tidal Investments LLC now owns 65,922 shares of the medical device company's stock valued at $4,440,000 after acquiring an additional 3,995 shares in the last quarter. Van Hulzen Asset Management LLC acquired a new position in DexCom in the 2nd quarter worth approximately $230,000. Scholtz & Company LLC boosted its stake in DexCom by 12.7% in the 2nd quarter. Scholtz & Company LLC now owns 77,334 shares of the medical device company's stock worth $5,208,000 after purchasing an additional 8,686 shares during the period. Finally, National Pension Service grew its position in DexCom by 3.9% during the 2nd quarter. National Pension Service now owns 660,309 shares of the medical device company's stock worth $44,472,000 after purchasing an additional 24,756 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of research reports. Truist Financial set a $93.00 target price on shares of DexCom and gave the stock a "buy" rating in a report on Friday, July 31st. JPMorgan Chase & Co. boosted their price objective on shares of DexCom from $65.00 to $82.00 and gave the company a "neutral" rating in a research report on Friday, July 31st. UBS Group set a $96.00 price objective on shares of DexCom and gave the stock a "buy" rating in a research note on Tuesday, July 28th. Weiss Ratings raised shares of DexCom from a "hold (c-)" rating to a "hold (c)" rating in a report on Tuesday, August 11th. Finally, BTIG Research reaffirmed a "buy" rating and set a $90.00 target price (up from $80.00) on shares of DexCom in a report on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $88.71.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company's products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.